WO2019011336A1 - Qaw-039的晶型及其制备方法和用途 - Google Patents

Qaw-039的晶型及其制备方法和用途 Download PDF

Info

Publication number
WO2019011336A1
WO2019011336A1 PCT/CN2018/095690 CN2018095690W WO2019011336A1 WO 2019011336 A1 WO2019011336 A1 WO 2019011336A1 CN 2018095690 W CN2018095690 W CN 2018095690W WO 2019011336 A1 WO2019011336 A1 WO 2019011336A1
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
crystal form
compound
preparation
crystalline form
Prior art date
Application number
PCT/CN2018/095690
Other languages
English (en)
French (fr)
Inventor
陈敏华
张炎锋
王金秋
钱佳乐
张晓宇
Original Assignee
苏州科睿思制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州科睿思制药有限公司 filed Critical 苏州科睿思制药有限公司
Publication of WO2019011336A1 publication Critical patent/WO2019011336A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the invention relates to the field of pharmaceutical crystal technology. Specifically, it relates to a crystal form of QAW-039 and a preparation method and use thereof.
  • QAW-039 (Fevipiprant) is a potential prostaglandin D2 receptor 2 antagonist for the treatment of asthma, atopic dermatitis and allergic rhinitis, developed by Novartis.
  • QAW-039 has achieved positive results in clinical trials. It can safely and effectively reduce eosinophilic airway inflammation in patients with moderate or severe asthma by reducing eosinophils that play a role in airway inflammation.
  • the patient's lung function and quality of life are expected to be innovative asthma drugs in recent decades.
  • WO2005123731A1 discloses a structure and a preparation method of the compound (I), and the inventors obtained a solid of the compound (I) according to the production method.
  • the solid has higher wettability and poorer stability than the crystalline form of the present invention.
  • the present inventors have found crystal forms CS1 and CS2 of the compound (I) excellent in properties.
  • the crystal form of the present invention is at least one of stability, melting point, solubility, in vitro and in vivo dissolution, wettability, bioavailability, adhesion, compressibility, fluidity, and processability, purification, formulation production, and the like. There are advantages, especially low wetting, good stability, high dissolution, and strong developability of the preparation, which provides a new and better choice for the development of drugs containing QAW-039, which is of great significance.
  • the main object of the present invention is to provide a novel crystalline form of the compound (I), a process for its preparation and use.
  • the present invention provides the crystal form CS1 of the compound (I) (hereinafter referred to as "crystal form CS1").
  • the X-ray powder diffraction of the crystal form CS1 has characteristic peaks at diffraction angle 2 ⁇ values of 12.0° ⁇ 0.2°, 14.2° ⁇ 0.2°, and 19.7° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystal form CS1 has characteristics at one, or two, or three points in the diffraction angle 2 ⁇ value of 17.4° ⁇ 0.2°, 21.1° ⁇ 0.2°, and 27.9° ⁇ 0.2°. peak.
  • the X-ray powder diffraction of the crystalline form CS1 has characteristic peaks at diffraction angle 2 ⁇ values of 17.4° ⁇ 0.2°, 21.1° ⁇ 0.2°, and 27.9° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystal form CS1 has characteristics at one, or two, or three of the diffraction angle 2 ⁇ values of 17.9° ⁇ 0.2°, 24.3° ⁇ 0.2°, and 26.1° ⁇ 0.2°. peak.
  • the X-ray powder diffraction of the crystalline form CS1 has characteristic peaks at diffraction angle 2 ⁇ values of 17.9° ⁇ 0.2°, 24.3° ⁇ 0.2°, and 26.1° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystal form CS1 has a diffraction angle 2 ⁇ value of 12.0° ⁇ 0.2°, 14.2° ⁇ 0.2°, 19.7° ⁇ 0.2°, 17.4° ⁇ 0.2°, 21.1° ⁇ 0.2°, Any of 3, 4, or 5, or 2, There are characteristic peaks at 6, or 7, or 8, or 9, or 10, or 11.
  • the X-ray powder diffraction pattern of Form CS1 is shown in FIG.
  • the present invention also provides a method for preparing a crystalline form CS1, characterized in that the method comprises:
  • the alcohol solvent in the method (1) is preferably methanol, or ethanol, or propanol, or any mixture thereof, and the crystallization time is preferably 0.5 to 24 hours;
  • the alcohol solvent in the method (1) is preferably methanol
  • the anti-solvent is preferably water
  • the crystallization time is preferably 2 hours.
  • the ketone solvent in the method (2) is preferably acetone, or methyl ethyl ketone, or methyl isobutyl ketone, or any mixture thereof, and the dissolution temperature is preferably 50 ° C, the cooling The temperature is preferably 4 ° C, and the crystallization time is preferably 4 to 48 hours;
  • the ketone solvent in the method (2) is preferably methyl ethyl ketone, and the crystallization time is preferably 24 hours.
  • the halogenated alkane solvent in the method (3) is preferably chloroform, and the nitrile solvent is preferably acetonitrile, and the volume ratio (v:v) of the halogenated alkane solvent to the nitrile solvent is preferably 1:15. -15:1, the stirring temperature was 5 °C.
  • volume ratio (v:v) of the halogenated alkane solvent to the nitrile solvent in the method (3) is preferably 3:1.
  • the present invention also provides the crystal form CS2 of the compound (I) (hereinafter referred to as "crystal form CS2").
  • the X-ray powder diffraction of the crystal form CS2 has a characteristic peak at a diffraction angle 2 ⁇ value of 11.5° ⁇ 0.2°, 16.5° ⁇ 0.2°, and 20.3° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystal form CS2 has characteristics at one, or two, or three of the diffraction angle 2 ⁇ values of 4.1° ⁇ 0.2°, 21.7° ⁇ 0.2°, and 22.4° ⁇ 0.2°. peak.
  • the X-ray powder diffraction of the crystalline form CS2 has characteristic peaks at diffraction angle 2 ⁇ values of 4.1° ⁇ 0.2°, 21.7° ⁇ 0.2°, and 22.4° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystal form CS2 has one, or two, or three places in the diffraction angle 2 ⁇ value of 5.0° ⁇ 0.2°, 22.9° ⁇ 0.2°, and 23.3° ⁇ 0.2°. Characteristic peaks.
  • the X-ray powder diffraction of the crystalline form CS2 has characteristic peaks at diffraction angle 2 ⁇ values of 5.0° ⁇ 0.2°, 22.9° ⁇ 0.2°, and 23.3° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS2 has a diffraction angle 2 ⁇ of 11.5° ⁇ 0.2°, 16.5° ⁇ 0.2°, 20.3° ⁇ 0.2°, 4.1° ⁇ 0.2°, 21.7° ⁇ 0.2°, Any 3, or 4, or 5, or 6, or 7, or 8 of 22.4 ° ⁇ 0.2 °, 5.0 ° ⁇ 0.2 °, 22.9 ° ⁇ 0.2 °, 23.3 ° ⁇ 0.2 °, or There are characteristic peaks at 9 places.
  • the X-ray powder diffraction pattern of Form CS2 is as shown in FIG.
  • the present invention also provides a method for preparing a crystalline form CS2, characterized in that the method comprises:
  • the alcohol solvent in the method (1) is preferably methanol, or ethanol, or isopropanol, or any mixture thereof
  • the halogenated hydrocarbon solvent is preferably chloroform, or dichloromethane, or Mixing
  • the volume ratio (v:v) of the alcohol and the halogenated hydrocarbon is preferably 1:5-5:1
  • the crystallization time is preferably 2-10 days;
  • the alcohol solvent in the method (1) is preferably methanol, and the halogenated hydrocarbon solvent is preferably chloroform, and the volume ratio (v:v) of the alcohol and the halogenated hydrocarbon solvent is preferably 3 :1, the crystallization time is preferably 7 days.
  • the cyclic ether solvent in the method (2) is preferably 1,4-dioxane, or tetrahydrofuran, or any mixture thereof, and the volume ratio (v:v) of the cyclic ether to water is preferably
  • the ketone solvent is preferably butanone, and the crystallization time is preferably 2 to 30 days;
  • the cyclic ether solvent in the method (2) is preferably tetrahydrofuran, and the volume ratio (v:v) of the cyclic ether to water is preferably 1:1, and the crystallization time is preferably 24 days.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form CS1, crystalline form CS2 of the present invention or any mixture thereof, and at least one pharmaceutically acceptable Carrier, diluent or excipient.
  • the use of the crystalline form CS1, the crystalline form CS2 or any mixture thereof provided by the present invention for the preparation of a pharmaceutical preparation for the treatment of asthma and/or atopic dermatitis and/or allergic rhinitis.
  • the crystal forms CS1 and CS2 provided by the present invention have the following beneficial effects:
  • the present invention provides a crystal form having lower wettability.
  • the weight gain of the prior art solids at 80% relative humidity is 1.43%, while the weight gains of the crystalline forms CS1 and CS2 of the present invention at 80% relative humidity are 0.65% and 0.61%, respectively.
  • Humidity affects the stability of the drug, fluidity and uniformity during processing, and ultimately affects the quality of the drug formulation. Humidity also affects the preparation, storage and post-treatment of the drug.
  • the low moisture absorbing crystal form has strict requirements on storage conditions, reduces material storage and quality control costs, and has strong economic value.
  • the crystalline bulk drug provided by the invention has good physical and chemical stability.
  • the crystal forms CS1 and CS2 provided by the invention are openly placed at 25 ° C / 60% relative humidity, 40 ° C / 75% relative humidity and 60 ° C / 75% relative humidity, and the crystal form remains unchanged for at least 6 months, preferably The crystal form can be kept at least for 1 year.
  • the crystal form of the present invention has a chemical purity of 98.5% or more, more preferably 99% or more, and the chemical purity remains substantially unchanged during the standing.
  • the crystalline form provided by the present invention has good physical and chemical stability in the formulation. After the crystalline forms CS1 and CS2 of the present invention are mixed with an auxiliary material to form a pharmaceutical preparation, and left at 25 ° C / 60% relative humidity and 40 ° C / 75% relative humidity for 3 months, the crystal form of the present invention remains unchanged in the preparation, and The chemical purity of the crystalline form in the formulation hardly changed.
  • the crystalline bulk drug and preparation have good physical and chemical stability.
  • the crystalline forms CS1 and CS2 are not converted into other crystalline forms, and the chemical purity of the crystalline forms CS1 and CS2 during storage is preserved. It remains basically unchanged, thus ensuring consistent quality control of the drug substance and preparation.
  • the crystal form provided by the present invention has good solubility in simulated biological medium and pure water. It provides a guarantee for the good dissolution of the crystal form in the preparation, and is beneficial to the effective absorption of the active ingredient in the preparation to achieve the desired bioavailability and efficacy of the medicine.
  • the crystal form of the present invention also has good dissolution and dissolution rate.
  • Dissolution is a prerequisite for absorption.
  • Good in vitro dissolution makes the absorption of the drug higher, and the in vivo exposure characteristics are better, thereby improving the bioavailability and improving the efficacy of the drug; a good in vitro dissolution rate allows the drug to be administered after the drug is administered. The highest concentration can be reached quickly in the plasma, thus ensuring rapid drug action.
  • the compound (I) as a raw material means a solid (crystalline or amorphous), semi-solid, wax or oil form.
  • the compound of formula (I) as a starting material is in the form of a solid powder.
  • crystal or “polymorph” means confirmed by the X-ray diffraction pattern characterization shown.
  • X-ray diffraction pattern will generally vary with the conditions of the instrument. It is particularly important to note that the relative intensities of the X-ray diffraction patterns may also vary with experimental conditions, so the order of peak intensities cannot be the sole or decisive factor. In fact, the relative intensity of the diffraction peaks in the XRPD pattern is related to the preferred orientation of the crystal.
  • the peak intensities shown here are illustrative and not for absolute comparison.
  • the experimental error of the peak angle is usually 5% or less, and the error of these angles should also be taken into account, and an error of ⁇ 0.2° is usually allowed.
  • the overall offset of the peak angle is caused, and a certain offset is usually allowed.
  • the X-ray diffraction pattern of one crystal form in the present invention is not necessarily identical to the X-ray diffraction pattern in the example referred to herein, and the "XRPD pattern is the same" as used herein does not mean absolutely the same.
  • the same peak position can differ by ⁇ 0.2° and the peak intensity allows for some variability.
  • Any crystal form having a map identical or similar to the characteristic peaks in these maps is within the scope of the present invention.
  • One skilled in the art will be able to compare the maps listed herein with a map of an unknown crystal form to verify whether the two sets of maps reflect the same or different crystal forms.
  • the crystalline forms CS1 and CS2 of the present invention are pure, unitary, and are substantially free of any other crystalline form.
  • substantially free when used to refer to a new crystalline form means that the crystalline form contains less than 20% by weight of other crystalline forms, especially less than 10% by weight of other crystalline forms, more Other crystal forms of 5% by weight, more preferably less than 1% by weight of other crystal forms.
  • Figure 1 is an XRPD pattern of a crystal form CS1 obtained according to Example 1 of the present invention.
  • Example 2 is a 1 H NMR chart of the crystal form CS1 obtained according to Example 1 of the present invention.
  • Figure 3 is a TGA diagram of a crystalline form CS1 obtained in accordance with Example 1 of the present invention.
  • Example 4 is an XRPD pattern of a crystal form CS1 obtained according to Example 3 of the present invention.
  • Figure 5 is an XRPD pattern of a crystalline form CS2 obtained according to Example 4 of the present invention.
  • Figure 6 is a 1 H NMR chart of the crystalline form CS2 obtained according to Example 4 of the present invention.
  • Figure 7 is a DSC chart of a crystalline form CS2 obtained according to Example 4 of the present invention.
  • Figure 8 is a TGA diagram of a crystalline form CS2 obtained in accordance with Example 4 of the present invention.
  • Figure 9 is an XRPD pattern of a crystalline form CS2 obtained according to Example 6 of the present invention.
  • Figure 10 is an XRPD pattern of the crystalline form CS1 of the present invention placed at 25 ° C / 60% relative humidity for 6 months (the top view is before placement and the lower figure is after placement).
  • Figure 11 is an XRPD pattern of the crystalline form CS1 of the present invention placed at 40 ° C / 75% relative humidity for 6 months (the top view is before placement and the lower figure is after placement).
  • Figure 12 is an XRPD pattern of the crystalline form CS1 of the present invention placed at 60 ° C / 75% relative humidity for 6 months (the top view is before placement and the lower figure is after placement).
  • Figure 13 is an XRPD pattern of the crystalline form CS2 of the present invention placed at 25 ° C / 60% relative humidity for 6 months (the top view is before placement and the lower figure is after placement).
  • Figure 14 is an XRPD pattern of the crystalline form CS2 of the present invention placed at 40 ° C / 75% relative humidity for 6 months (the top view is before placement and the lower figure is after placement).
  • Figure 15 is an XRPD pattern of the crystalline form CS2 of the present invention placed at 60 ° C / 75% relative humidity for 6 months (the top view is before placement and the lower figure is after placement).
  • Figure 16 is an in vitro dissolution profile of a crystalline form CS1 tablet of the present invention.
  • Figure 17 is an in vitro dissolution profile of a crystalline form CS2 tablet of the present invention.
  • the invention is further defined by the following examples which describe in detail the preparation and use of the crystalline forms of the invention.
  • the X-ray powder diffraction pattern of the present invention was collected on a Panalytical Empyrean X-ray powder diffractometer.
  • the method parameters of the X-ray powder diffraction described in the present invention are as follows:
  • Scan range: from 3.0 to 40.0 degrees
  • the differential scanning calorimetry (DSC) map of the present invention was acquired on a TA Q2000.
  • the method parameters of the differential scanning calorimetry (DSC) described in the present invention are as follows:
  • thermogravimetric analysis (TGA) map of the present invention was taken on a TA Q500.
  • the method parameters of the thermogravimetric analysis (TGA) described in the present invention are as follows:
  • the dynamic moisture adsorption (DVS) pattern of the present invention was collected on an Intrinsic dynamic moisture adsorber manufactured by SMS Corporation (Surface Measurement Systems Ltd.).
  • the method parameters of the dynamic moisture adsorber are as follows:
  • Relative humidity range 0%RH-95%RH
  • HPLC high performance liquid chromatography
  • HPLC high performance liquid chromatography
  • H NMR data (1 HNMR) collected from a Bruker Avance II DMX 400M HZ NMR spectrometer. A sample of 1-5 mg was weighed and dissolved in 0.5 mL of deuterated dimethyl sulfoxide to prepare a solution of 2-10 mg/mL.
  • room temperature is not an accurate temperature value and refers to a temperature range of 10-30 °C.
  • the QAW-039 used in the following examples was prepared according to the prior art.
  • the prior art solids in the following examples were obtained according to the preparation methods disclosed in WO2005123731A1.
  • the nuclear magnetic resonance spectrum is shown in Fig. 2.
  • the TGA of the crystal form CS1 obtained in this example is as shown in Fig. 3, and has a weight loss of about 0.4% when heated to around 150 °C.
  • the nuclear magnetic resonance spectrum is shown in Fig. 6.
  • the DSC of the crystalline form CS2 obtained in this example is as shown in Fig. 7, and an endothermic peak appears near the temperature of 175 ° C, which is the melting endothermic peak of the crystalline form CS2.
  • the TGA of the form CS2 obtained in this example is as shown in Fig. 8, and has a weight loss of about 3.2% when heated to around 150 °C.
  • Example 7 Comparison of wettability of crystalline forms CS1, CS2 and prior art solids
  • the wettability of the crystalline forms CS1, CS2 of the present invention and about 10 mg of the prior art solids were measured by dynamic moisture adsorption (DVS) at 25 ° C.
  • the test results are shown in Table 5 below. The results show that the crystalline forms CS1 and CS2 of the present invention have lower wettability than the prior art solids.
  • Example 8 Stability of Forms CS1 and CS2
  • the crystal form CS1 of the present invention has no change in crystal form after being left for 6 months under the conditions of 25 ° C / 60% relative humidity, 40 ° C / 75% relative humidity and 60 ° C / 75% relative humidity, and the chemical purity of the crystal form is basically It remains unchanged, indicating that the crystalline form CS1 of the present invention has good physical and chemical stability.
  • the crystalline form CS2 of the present invention does not change crystal form after being left for 6 months at 25 ° C / 60% relative humidity, 40 ° C / 75% relative humidity and 60 ° C / 75% relative humidity; and at 25 ° C / 60% relative Under the conditions of humidity and 40 ° C / 75% relative humidity, the chemical purity of the crystal form remained basically unchanged after standing for 6 months, indicating that the crystalline form CS2 of the present invention has good physical and chemical stability.
  • Example 9 Dynamic solubility of crystalline forms CS1 and CS2
  • Gastrointestinal fluids such as SGF (simulated gastric fluid), FaSSIF (simulated fasting intestinal fluid), FeSSIF (simulated feeding intestinal fluid) are biologically relevant media, and such media can better reflect the gastrointestinal physiological environment for drug release.
  • SGF simulated gastric fluid
  • FaSSIF simulated fasting intestinal fluid
  • FeSSIF simulated feeding intestinal fluid
  • the crystalline forms CS1 and CS2 of the present invention are respectively dissolved in a saturated solution prepared by SGF, FaSSIF, FeSSIF and water, and after 1 hour of equilibrium, the content of the sample in the saturated solution is measured by high performance liquid chromatography (HPLC) ( ⁇ g/ml). The results are shown in Table 10.
  • crystal form of the compound (I) (crystal form CS1 or CS2), microcrystalline cellulose, croscarmellose sodium and magnesium stearate (the contents of the respective components are shown in Table 11) were weighed and mixed for 2 minutes. . It was pressed into a piece by a manual tableting machine, and a circular die of 6 mm in diameter was pressed at a pressure of 5 KN ⁇ 1 KN, and the tablet weight was 75 mg ⁇ 1 mg. The crystal form of the active ingredient was not changed before and after preparation of the preparation.
  • the tablets prepared above were packaged in 35 cc HDPE bottles (one tablet per bottle) containing 1 g of desiccant per bottle and sealed with a sealer. Placed at 25 ° C / 60% relative humidity and 40 ° C / 75% relative humidity for 3 months, tested, in the tablets containing crystalline form CS1 and CS2, the crystal form did not change, and during the placement of crystal Type CS1 and CS2 chemistry
  • Example 11 In vitro dissolution and in vitro dissolution rate of crystalline form CS1
  • the tablets containing the crystalline form CS1 obtained in Example 10 were tested for in vitro dissolution, and the dissolution was measured according to the Chinese Pharmacopoeia 2015 edition 0931 dissolution and release assay conditions as follows:
  • Dissolution method paddle method
  • Example 12 In vitro dissolution and in vitro dissolution rate of crystalline CS2
  • the CS2-containing tablets obtained in Example 10 were tested for in vitro dissolution, and the dissolution was measured according to the Chinese Pharmacopoeia 2015 edition 0931 dissolution and release assay conditions as follows:
  • Dissolution method paddle method

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及化合物(I)的晶型及其制备方法和用途，含有该晶型的药物组合物，以及该晶型在制备前列腺素D2受体2拮抗剂和治疗哮喘或过敏性皮炎或过敏性鼻炎药物制剂中的用途。本发明提供的晶型引湿性低、稳定性好、溶出度高、制剂可开发性强，为含化合物(I)的药物开发提供了新的更好的选择，具有非常重要的意义。

Description

QAW-039的晶型及其制备方法和用途 技术领域
本发明涉及药物晶体技术领域。具体而言，涉及QAW-039的晶型及其制备方法和用途。
背景技术
QAW-039(Fevipiprant)是一种潜在的治疗哮喘、过敏性皮炎和过敏性鼻炎的前列腺素D2受体2拮抗剂，由诺华研发。QAW-039在临床试验中取得了积极的效果，通过减少在气道炎症中起作用的嗜酸性粒细胞，可以安全有效地降低中度或重度哮喘患者的嗜酸性粒细胞气道炎症反应，改善患者的肺功能和生活质量，有望成为近几十年来的创新型哮喘药物。
QAW-039的化学名称为：[1-(4-((甲烷)磺酰基)-2-三氟甲基苯甲基)-2-甲基-1H-吡咯并[2,3-b]吡啶-3-基]乙酸(以下称为“化合物(I)”)，其结构式如下：
Figure PCTCN2018095690-appb-000001
目前，无化合物(I)的晶型信息公开。WO2005123731A1公开了化合物(I)的结构和制备方法，发明人根据该制备方法得到了化合物(I)的固体。与本发明的晶型相比，该固体的引湿性较高，且稳定性较差。本发明人发现了性质优良的化合物(I)的晶型CS1和CS2。本发明的晶型在稳定性、熔点、溶解度、体内外溶出、引湿性、生物有效性、黏附性、可压性、流动性以及加工性能、提纯作用、制剂生产等方面中的至少一方面上存在优势，特别是引湿性低、稳定性好、溶出度高、制剂可开发性强，为含QAW-039的药物开发提供了新的更好的选择，具有非常重要的意义。
发明内容
本发明的主要目的是提供化合物(I)的新晶型及其制备方法和用途。
根据本发明的目的，本发明提供化合物(I)的晶型CS1(以下称作“晶型CS1”)。
一方面，使用Cu-Kα辐射，所述晶型CS1的X射线粉末衍射在衍射角2θ值为12.0°±0.2°、 14.2°±0.2°、19.7°±0.2°处有特征峰。
进一步地，所述晶型CS1的X射线粉末衍射在衍射角2θ值为17.4°±0.2°、21.1°±0.2°、27.9°±0.2°中的1处、或2处、或3处有特征峰。优选的，所述晶型CS1的X射线粉末衍射在衍射角2θ值为17.4°±0.2°、21.1°±0.2°、27.9°±0.2°处均有特征峰。
进一步地，所述晶型CS1的X射线粉末衍射在衍射角2θ值为17.9°±0.2°、24.3°±0.2°、26.1°±0.2°中的1处、或2处、或3处有特征峰。优选的，所述晶型CS1的X射线粉末衍射在衍射角2θ值为17.9°±0.2°、24.3°±0.2°、26.1°±0.2°处均有特征峰。
另一方面，所述晶型CS1的X射线粉末衍射在衍射角2θ值为12.0°±0.2°、14.2°±0.2°、19.7°±0.2°、17.4°±0.2°、21.1°±0.2°、27.9°±0.2°、17.9°±0.2°、24.3°±0.2°、26.1°±0.2°、15.7°±0.2°、22.1°±0.2°中的任意3处、或4处、或5处、或6处、或7处、或8处、或9处、或10处、或11处有特征峰。
非限制性地，在本发明的一个具体实施方案中，晶型CS1的X射线粉末衍射谱图如图1所示。
根据本发明的目的，本发明还提供晶型CS1的制备方法，其特征在于，所述方法包括：
(1)将化合物(I)原料溶解在醇类溶剂中，添加反溶剂析晶，然后分离、干燥而获得；或
(2)化合物(I)原料在40-70℃温度下溶解在酮类溶剂中，并于0-30℃条件下冷却析晶，分离，干燥得到；或
(3)将化合物(I)原料加至卤代烷烃和腈类的混合溶剂中，于0-30℃条件下搅拌析晶得到。
进一步地，方法(1)中所述醇类溶剂优选为甲醇、或乙醇、或丙醇、或它们的任意混合，所述析晶时间优选为0.5-24小时；
更进一步地，方法(1)中所述醇类溶剂优选为甲醇，所述反溶剂优选为水，所述析晶时间优选为2小时。
进一步地，方法(2)中所述酮类溶剂优选为丙酮、或甲基乙基酮、或甲基异丁基酮、或它们的任意混合，所述溶解温度优选为50℃，所述冷却温度优选为4℃，所述析晶时间优选为4-48小时；
更进一步地，方法(2)中所述酮类溶剂优选为甲基乙基酮，所述析晶时间优选为24小时。
进一步地，方法(3)中所述卤代烷烃类溶剂优选为氯仿，所述腈类溶剂优选为乙腈，所述卤代烷烃类溶剂和腈类溶剂的体积比(v:v)优选为1:15-15:1，所述搅拌温度为5℃。
更进一步的，方法(3)中所述卤代烷烃类溶剂和腈类溶剂的体积比(v:v)优选为3:1。
根据本发明的目的，本发明还提供化合物(I)的晶型CS2(以下称作“晶型CS2”)。
一方面，使用Cu-Kα辐射，所述晶型CS2的X射线粉末衍射在衍射角2θ值为11.5°±0.2°、16.5°±0.2°、20.3°±0.2°处有特征峰。
进一步地，所述晶型CS2的X射线粉末衍射在衍射角2θ值为4.1°±0.2°、21.7°±0.2°、22.4°±0.2°中的1处、或2处、或3处有特征峰。优选的，所述晶型CS2的X射线粉末衍射在衍射角2θ值为4.1°±0.2°、21.7°±0.2°、22.4°±0.2°处均有特征峰。
更进一步地，所述晶型CS2的X射线粉末衍射在衍射角2θ值为5.0°±0.2°、22.9°±0.2°、23.3°±0.2°中的1处、或2处、或3处有特征峰。优选的，所述晶型CS2的X射线粉末衍射在衍射角2θ值为5.0°±0.2°、22.9°±0.2°、23.3°±0.2°处均有特征峰。
另一方面，所述晶型CS2的X射线粉末衍射在衍射角2θ值为11.5°±0.2°、16.5°±0.2°、20.3°±0.2°、4.1°±0.2°、21.7°±0.2°、22.4°±0.2°、5.0°±0.2°、22.9°±0.2°、23.3°±0.2°中的任意3处、或4处、或5处、或6处、或7处、或8处、或9处有特征峰。
非限制性地，在本发明的一个具体实施方案中，晶型CS2的X射线粉末衍射谱图如附图5所示。
根据本发明的目的，本发明还提供晶型CS2的制备方法，其特征在于，所述方法包括：
(1)将化合物(I)原料溶解在醇类和卤代烃类的混合溶剂中，后挥发而获得；或
(2)将化合物(I)原料溶解在环醚类和水的混合溶剂或酮类溶剂中，后挥发而获得。
进一步地，方法(1)中所述醇类溶剂优选为甲醇、或乙醇、或异丙醇、或它们的任意混合，所述卤代烃类溶剂优选为氯仿、或二氯甲烷、或者它们的混合，所述醇类和卤代烃的体积比(v:v)优选为1:5-5:1，所述析晶时间优选为2-10天；
更进一步地，方法(1)中所述醇类溶剂优选为甲醇，所述卤代烃类溶剂优选为氯仿，所述醇类和卤代烃类溶剂的体积比(v:v)优选为3:1，所述析晶时间优选为7天。
进一步地，方法(2)中所述环醚类溶剂优选为1,4-二氧六环、或四氢呋喃、或者它们的任意混合，所述环醚类和水的体积比(v:v)优选为1:10-10:1，所述酮类溶剂优选为丁酮，所述析晶时间优选为2-30天；
更进一步地，方法(2)中所述环醚类溶剂优选为四氢呋喃，所述环醚类和水的体积比(v:v)优选为1:1，所述析晶时间优选为24天。
根据本发明的目的，本发明还提供一种药物组合物，所述药物组合物包含有效治疗量的本发明的晶型CS1、晶型CS2或它们的任意混合，以及至少一种药学上可接受的载体、稀释剂或赋形剂。
进一步地，本发明提供的晶型CS1、晶型CS2或它们的任意混合在制备前列腺素D2受体2拮抗剂药物制剂中的用途。
更进一步地，本发明提供的晶型CS1、晶型CS2或它们的任意混合在制备治疗治疗哮喘和/或过敏性皮炎和/或过敏性鼻炎药物制剂中的用途。
本发明提供的晶型CS1和CS2具有以下有益效果：
(1)与现有技术相比，本发明提供的晶型引湿性更低。现有技术固体在80％相对湿度下的增重量为1.43％，而本发明晶型CS1和晶型CS2在80％相对湿度的增重量分别为0.65％和0.61％。
引湿性会影响药物的稳定性、加工时的流动性和均匀性等，最终影响药物制剂的质量。引湿性还会影响药物的制备、储存与后处理工艺。低引湿性晶型对储存条件要求不苛刻，降低了物料储存以及质量控制成本，具有很强的经济价值。
(2)本发明提供的晶型具有良好的稳定性。
本发明提供的晶型原料药具有良好的物理、化学稳定。本发明提供的晶型CS1和CS2在25℃/60％相对湿度、40℃/75％相对湿度和60℃/75％相对湿度下敞口放置，至少放置6个月晶型保持不变，优选的可至少放置1年晶型保持不变。本发明晶型的化学纯度在98.5％以上，更优选的在99％以上，且在放置过程中化学纯度基本保持不变。
本发明提供的晶型在制剂中具有良好的物理、化学稳定性。本发明晶型CS1和CS2与辅料混合做成药物制剂后，在25℃/60％相对湿度和40℃/75％相对湿度下放置3个月，制剂中本发明的晶型保持不变，且制剂中晶型的化学纯度几乎不发生改变。
晶型原料药和制剂具有良好的物理、化学稳定性，在存储和制剂工艺过程中，晶型CS1和CS2不会转变成其它晶型，且在储存过程中，晶型CS1和CS2的化学纯度基本保持不变，从而保证原料药和制剂的质量一致可控。
(3)本发明提供的晶型在模拟生物介质和纯水中具有良好的溶解度。为制剂中晶型的良好溶出提供保障，有利于制剂中活性成分在人体内的有效吸收，达到理想的药物生物利用度和药效。
(4)本发明晶型还具有良好的溶出度和溶出速率。本发明的晶型CS1和CS2在pH＝6.8磷酸盐缓冲溶液介质中，60min时的溶出度达70～95％，有利于其在体内的良好吸收，达到理想的生物利用度。
溶出是吸收的前提条件，良好的体外溶出度使得药物的吸收程度较高，在体内暴露特性更好，从而提高生物利用度，提高药物的疗效；良好的体外溶出速率使得药物在给药后药物在血浆中能够很快达到最高浓度值，进而确保药物快速起效。
根据本发明，作为原料的所述化合物(I)指其固体(晶型或无定形)、半固体、蜡或油形式。优选地，作为原料的所述式(I)化合物为固体粉末形式。
本发明中，“晶体”或“多晶型”指的是被所示的X射线衍射图表征所证实的。本领域技术人员能够理解，这里所讨论的理化性质可以被表征，其中的实验误差取决于仪器的条件、样品的准备和样品的纯度。特别是，本领域技术人员公知，X射线衍射图通常会随着仪器的条件而有所改变。特别需要指出的是，X射线衍射图的相对强度也可能随着实验条件的变化而变化，所以峰强度的顺序不能作为唯一或决定性因素。事实上，XRPD图谱中衍射峰的相对强度与晶体的择优取向有关，本文所示的峰强度为说明性而非用于绝对比较。另外，峰角度的实验误差通常在5％或更少，这些角度的误差也应该被考虑进去，通常允许有±0.2°的误差。另外，由于样品高度等实验因素的影响，会造成峰角度的整体偏移，通常允许一定的偏移。因而，本领域技术人员可以理解的是，本发明中一个晶型的X射线衍射图不必和这里所指的例子中的X射线衍射图完全一致，本文所述“XRPD图相同”并非指绝对相同，相同峰位置可相差±0.2°且峰强度允许一定可变性。任何具有和这些图谱中的特征峰相同或相似的图的晶型均属于本发明的范畴之内。本领域技术人员能够将本发明所列的图谱和一个未知晶型的图谱相比较，以证实这两组图谱反映的是相同还是不同的晶型。
在一些实施方案中，本发明的晶型CS1和CS2是纯的、单一的，基本没有混合任何其他晶型。本发明中，“基本没有”当用来指新晶型时指这个晶型含有少于20％(重量)的其他晶型，尤其指少于10％(重量)的其他晶型，更指少于5％(重量)的其他晶型，更指少于1％(重量)的其他晶型。
需要说明的是，本发明中提及的数值及数值范围不应被狭隘地理解为数值或数值范围本身，本领域技术人员应当理解其可以根据具体技术环境的不同，在不背离本发明精神和原则的基础上围绕具体数值有所浮动，本发明中，这种本领域技术人员可预见的浮动范围多以术语“约”来表示。
附图说明
图1为根据本发明实施例1所得晶型CS1的XRPD图。
图2为根据本发明实施例1所得晶型CS1的 1HNMR图。
图3为根据本发明实施例1所得晶型CS1的TGA图。
图4为根据本发明实施例3所得晶型CS1的XRPD图。
图5为根据本发明实施例4所得晶型CS2的XRPD图。
图6为根据本发明实施例4所得晶型CS2的 1HNMR图。
图7为根据本发明实施例4所得晶型CS2的DSC图。
图8为根据本发明实施例4所得晶型CS2的TGA图。
图9为根据本发明实施例6所得晶型CS2的XRPD图。
图10为本发明晶型CS1在25℃/60％相对湿度条件下放置6个月前后的XRPD图(上图为放置前，下图为放置后)。
图11为本发明晶型CS1在40℃/75％相对湿度条件下放置6个月前后的XRPD图(上图为放置前，下图为放置后)。
图12为本发明晶型CS1在60℃/75％相对湿度条件下放置6个月前后的XRPD图(上图为放置前，下图为放置后)。
图13为本发明晶型CS2在25℃/60％相对湿度条件下放置6个月前后的XRPD图(上图为放置前，下图为放置后)。
图14为本发明晶型CS2在40℃/75％相对湿度条件下放置6个月前后的XRPD图(上图为放置前，下图为放置后)。
图15为本发明晶型CS2在60℃/75％相对湿度条件下放置6个月前后的XRPD图(上图为放置前，下图为放置后)。
图16为本发明晶型CS1片剂的体外溶出曲线。
图17为本发明晶型CS2片剂的体外溶出曲线。
具体实施方式
本发明进一步参考以下实施例限定，所述实施例详细描述本发明的晶型的制备和使用方法。
本发明中所用到的缩写的解释如下：
XRPD：X射线粉末衍射
DSC：差示扫描量热分析
TGA：热重分析
DVS：动态水分吸附
HPLC：高效液相色谱
1HNMR：核磁共振氢谱
采集数据所用的仪器及方法：
本发明所述的X射线粉末衍射图在Panalytical Empyrean X射线粉末衍射仪上采集。本发明所述的X射线粉末衍射的方法参数如下：
X射线反射参数：Cu,Kα
Kα1
Figure PCTCN2018095690-appb-000002
：1.540598；Kα2
Figure PCTCN2018095690-appb-000003
：1.544426
Kα2/Kα1强度比例：0.50
电压：45仟伏特(kV)
电流：40毫安培(mA)
扫描范围：自3.0至40.0度
本发明所述的差示扫描量热分析(DSC)图在TA Q2000上采集。本发明所述的差示扫描量热分析(DSC)的方法参数如下：
扫描速率：如无特别说明为10℃/min
保护气体：N 2
本发明所述的热重分析(TGA)图在TA Q500上采集。本发明所述的热重分析(TGA)的方法参数如下：
扫描速率：10℃/min
保护气体：N 2
本发明所述动态水分吸附(DVS)图在由SMS公司(Surface Measurement Systems Ltd.)生产的Intrinsic动态水分吸附仪上采集。所述的动态水分吸附仪的方法参数如下：
温度：25℃
载气，流速：N 2,200毫升/分钟
单位时间质量变化：0.002％/分钟
相对湿度范围：0％RH-95％RH
测试晶型化学纯度的HPLC仪器参数：
高效液相色谱(HPLC)数据采集来自于安捷伦1260，所用检测器为紫外可变波长检测器(VWD)。本发明所述的HPLC方法参数如下：
色谱柱：Xbridge C8,150×4.6mm,3.5μm
流动相：A:0.1％TFA in H 2O
B:0.1％TFA in acetonitrile
洗脱梯度：
Time(min) ％B
0.0 15
20.0 80
25.0 80
26.0 15
32.0 15
流速：1.0mL/min
进样量：5μL
柱温：40℃
稀释剂：ACN:H 2O＝1:1
测试溶解度的HPLC仪器参数：
高效液相色谱(HPLC)数据采集来自于安捷伦1260，所用检测器为紫外可变波长检测器(VWD)。本发明所述的HPLC方法参数如下：
色谱柱：Xbridge C18,150×4.6mm,5μm
流动相：A:0.1％TFA in H 2O
B:0.1％TFA in acetonitrile
洗脱梯度：
Time(min) ％B
0.0 40
8.0 40
流速：1.0mL/min
进样量：5μL
柱温：40℃
稀释剂：ACN:H 2O＝1:1
核磁共振氢谱数据( 1HNMR)采自于Bruker Avance II DMX 400M HZ核磁共振波谱仪。称量1-5mg样品，用0.5mL氘代二甲亚砜溶解，配成2-10mg/mL的溶液。
除非特殊说明，以下实施例均在室温条件下操作。所述“室温”不是精确的温度值，是指10-30℃温度范围。
以下实施例中所使用到的QAW-039是根据现有技术制备得到。以下实施例中的现有技术固体是根据WO2005123731A1中公开的制备方法得到。
实施例1～3：晶型CS1的制备方法
实施例1
将5.6mg的化合物(I)溶解于0.3mL甲醇溶剂中，过滤后滴加2.0mL的反溶剂水，室温下搅拌析晶2小时，离心后于室温下真空干燥得到结晶固体。经检测，所得结晶固体为晶型CS1，其X射线粉末衍射数据如图1，表1所示。
核磁共振氢谱谱图如图2所示，核磁数据为： 1H NMR(400MHz,DMSO)δ8.26(s,1H), 8.14(d,J＝3.7Hz,1H),8.04(d,J＝8.3Hz,1H),7.95(d,J＝7.8Hz,1H),7.12(dd,J＝7.8,4.7Hz,1H),6.49(d,J＝8.3Hz,1H),5.76(s,2H),3.73(s,2H),3.28(s,3H),2.28(s,3H)。
本实施例所得晶型CS1的TGA如附图3所示，加热至150℃附近时具有约0.4％的失重。
表1
衍射角2θ d值 强度％
10.43 8.48 15.45
11.96 7.40 100.00
14.22 6.23 67.17
15.66 5.66 17.26
17.39 5.10 47.26
17.85 4.97 45.32
18.11 4.90 57.17
19.74 4.50 45.73
20.63 4.30 20.71
21.07 4.22 73.17
21.29 4.17 53.17
22.12 4.02 18.85
23.94 3.72 33.06
24.28 3.67 55.92
26.07 3.42 34.06
27.38 3.26 13.86
27.92 3.20 48.28
29.49 3.03 7.81
31.05 2.88 9.33
32.28 2.77 8.01
35.72 2.51 4.56
36.84 2.44 3.40
实施例2
在50℃下将7.8mg的化合物(I)溶解于0.3mL的甲基乙基酮溶剂中，过滤后于4℃下冷却析晶24小时，离心后于室温下真空干燥得到结晶固体。经检测，所得结晶固体为晶型CS1。
实施例3
将8.2mg的化合物(I)加入0.2mL体积比为3:1的氯仿和乙腈的混合溶剂中，5℃下搅拌析晶24小时，离心，室温下真空干燥得到固体。经检测，所得结晶固体为本发明的晶型CS1，其X射线粉末衍射数据如图4、表2所示。
表2
衍射角2θ d值 强度％
10.43 8.48 10.67
11.96 7.40 100.00
14.20 6.24 66.98
15.69 5.65 28.99
17.41 5.09 65.87
17.85 4.97 51.98
18.11 4.90 56.67
19.79 4.49 57.59
20.61 4.31 18.87
21.08 4.22 70.52
21.29 4.17 49.11
22.11 4.02 24.76
23.94 3.72 36.92
24.25 3.67 64.40
26.03 3.42 34.10
27.33 3.26 13.74
27.93 3.19 53.27
29.47 3.03 6.03
31.04 2.88 15.86
32.13 2.79 5.35
实施例4～6：晶型CS2的制备方法
实施例4
将18.4mg的化合物(I)加入到2.0mL体积比为3:1的甲醇和氯仿的混合溶剂中，溶解过滤，于室温下挥发约7天析出固体。经检测，所得固体为晶型CS2，其X射线粉末衍射数据如图5、表3所示。
核磁共振氢谱谱图如图6所示，核磁数据为： 1H NMR(400MHz,DMSO)δ8.26(s,1H),8.14(d,J＝3.8Hz,1H),8.04(d,J＝8.6Hz,1H),7.95(d,J＝7.7Hz,1H),7.12(dd,J＝7.8,4.7 Hz,1H),6.49(d,J＝8.2Hz,1H),5.76(s,2H),3.73(s,2H),3.28(s,3H),2.28(s,3H).
本实施例所得晶型CS2的DSC如附图7所示，加热至175℃附近开始出现一个吸热峰，该吸热峰是晶型CS2的熔化吸热峰。
本实施例所得晶型CS2的TGA如附图8所示，加热至150℃附近时具有约3.2％的失重。
表3
衍射角2θ d值 强度％
4.05 21.81 29.51
4.99 17.69 15.16
8.60 10.28 9.21
11.52 7.68 72.97
12.33 7.18 13.30
14.37 6.16 8.03
14.85 5.97 15.40
15.17 5.84 8.30
16.17 5.48 17.77
16.48 5.38 100.00
17.63 5.03 10.86
18.32 4.84 15.59
18.95 4.68 13.15
19.91 4.46 26.07
20.36 4.36 42.31
20.91 4.25 19.41
21.22 4.19 23.32
21.66 4.10 34.29
22.37 3.98 33.83
22.92 3.88 30.68
23.30 3.82 25.25
23.87 3.73 13.19
24.79 3.59 11.84
25.53 3.49 6.29
26.13 3.41 6.44
26.74 3.33 9.17
27.24 3.27 6.30
28.14 3.17 11.66
29.10 3.07 14.97
30.04 2.98 5.55
31.06 2.88 7.63
32.98 2.72 6.84
35.30 2.54 5.20
实施例5
将约7.0mg的化合物(I)加入到1.0mL体积比为1:1的四氢呋喃和水的混合溶剂中，溶解过滤，于室温下挥发约24天至析出固体。经检测，所得固体为晶型CS2。
实施例6：
将22.7mg的化合物(I)加至1.5mL丁酮中，溶解过滤，室温下挥发至析出固体。经检测，所得固体为晶型CS2，其X射线粉末衍射数据如图9、表4所示。
表4
衍射角2θ d值 强度％
4.04 21.88 24.04
4.97 17.77 14.28
7.09 12.46 8.18
8.62 10.26 8.55
11.53 7.67 51.47
12.26 7.22 14.85
14.34 6.18 13.30
14.83 5.97 17.98
15.17 5.84 14.68
16.15 5.49 13.37
16.48 5.38 100.00
17.60 5.04 22.67
18.28 4.85 20.68
18.95 4.68 10.03
19.90 4.46 19.36
20.29 4.38 50.93
21.21 4.19 18.05
21.64 4.11 37.83
22.34 3.98 33.74
22.89 3.89 21.29
23.28 3.82 16.00
23.84 3.73 11.20
24.78 3.59 12.47
25.42 3.50 7.71
26.10 3.41 6.11
26.72 3.34 10.83
28.14 3.17 13.60
29.05 3.07 11.91
30.00 2.98 4.63
31.09 2.88 4.98
32.95 2.72 7.73
35.29 2.54 3.59
37.62 2.39 1.78
实施例7：晶型CS1、CS2和现有技术固体的引湿性对比
在25℃条件下，取本发明的晶型CS1、CS2和现有技术固体各约10mg进行动态水分吸附(DVS)测试其引湿性，测试结果如下表5所示。结果表明，与现有技术固体相比，本发明的晶型CS1和CS2的具有更低的引湿性。
表5
晶型 80％相对湿度下增重量
CS1 0.65％
CS2 0.61％
现有技术固体 1.43％
实施例8：晶型CS1和CS2的稳定性
取本发明晶型CS1的样品分别置于25℃/60％相对湿度、40℃/75％相对湿度和60℃/75％相对湿度下敞口放置，测试放置前后晶型和化学纯度的变化，结果如表6和表7所示：
表6
Figure PCTCN2018095690-appb-000004
表7
Figure PCTCN2018095690-appb-000005
本发明晶型CS1在25℃/60％相对湿度、40℃/75％相对湿度和60℃/75％相对湿度条件下，放置6个月后晶型未发生改变，且晶型的化学纯度基本保持不变，说明本发明晶型CS1具有良好的物理、化学稳定性。
取本发明晶型CS2的样品分别置于25℃/60％相对湿度、40℃/75％相对湿度和60℃/75％相对湿度条件下敞口放置，测试放置前后晶型和化学纯度的变化，结果如表8和表9所示：
表8
Figure PCTCN2018095690-appb-000006
表9
Figure PCTCN2018095690-appb-000007
本发明晶型CS2在25℃/60％相对湿度、40℃/75％相对湿度和60℃/75％相对湿度条件下放置6个月后晶型未发生改变；且在25℃/60％相对湿度和40℃/75％相对湿度条件下，放置6个月后晶型的化学纯度基本保持不变，说明本发明晶型CS2具有良好的物理、化学稳定性。
实施例9：晶型CS1和CS2的动态溶解度
胃肠道液体例如SGF(模拟胃液)、FaSSIF(模拟禁食状态肠液)、FeSSIF(模拟喂食状态肠液)属于生物相关介质，此类介质能更好地反映胃肠道生理环境对药物释放产生的影响，在此类介质中测试的溶解度与人体环境中的溶解度更加接近。
取本发明的晶型CS1和CS2，分别溶于SGF、FaSSIF、FeSSIF和水配制成的饱和溶液，平衡1小时后用高效液相色谱(HPLC)测试饱和溶液中样品的含量(微克/毫升)，结果如表10所示。
表10晶型CS1和CS2在SGF、FeSSIF、FaSSIF和水中的溶解度
Figure PCTCN2018095690-appb-000008
结果表明，本发明晶型CS1和CS2在SGF，FeSSIF，FaSSIF和纯水中具有良好的溶解度。
实施例10：晶型CS1和CS2的制剂
1.化合物(I)片剂的制备：
称取化合物(I)的晶型(晶型CS1或CS2)、微晶纤维素、交联羧甲基纤维素钠和硬脂酸镁(各组分含量如表11所示)，混合2分钟。用手动压片机压制成片，直径6mm圆形冲模，压力5KN±1KN，片重75mg±1mg。经检测，制剂制备前后，活性成分的晶型未发生变化。
表11
片剂成分 质量(mg/片) 质量比(％)
晶型CS1或CS2 15 20
微晶纤维素 55.5 74
交联羧甲基纤维素钠 3.75 5
硬脂酸镁 0.75 1
合计 75 100
2.晶型CS1和CS2在制剂中的稳定性
上述制备的片剂用35cc HDPE瓶包装(每瓶一片)，每瓶含有1g干燥剂，用封口机封口。在25℃/60％相对湿度和40℃/75％相对湿度条件下放置3个月，经检测，在含晶型CS1和CS2的片剂中，晶型未发生变化，且在放置过程中晶型CS1和CS2的化学
基本不变。结果分别如下表12和表13所示，说明晶型CS1和CS2在制剂中具有很好的物理、化学稳定性。
表12晶型CS1在制剂中的稳定性
Figure PCTCN2018095690-appb-000009
表13晶型CS2在制剂中的稳定性
Figure PCTCN2018095690-appb-000010
实施例11晶型CS1的体外溶出度与体外溶出速率
对实施例10获得的含晶型CS1的片剂测试体外溶出情况，溶出度的测定按照中国药典2015年版0931溶出度与释放度测定法，条件如下：
溶出介质：pH＝6.8磷酸盐缓冲溶液
溶出方法：桨法
介质体积：900mL
转速：75rpm
介质温度：37℃
晶型CS1的体外溶出情况如表14，图16所示，表明以本发明晶型CS1为活性成分的片剂具有良好的溶出度和溶出速率。
表14
Figure PCTCN2018095690-appb-000011
Figure PCTCN2018095690-appb-000012
实施例12晶型CS2的体外溶出度与体外溶出速率
对实施例10获得的含CS2的片剂测试体外溶出情况，溶出度的测定按照中国药典2015年版0931溶出度与释放度测定法，条件如下：
溶出介质：pH＝6.8磷酸盐缓冲溶液
溶出方法：桨法
介质体积：900mL
转速：75rpm
介质温度：37℃
晶型CS2的体外溶出情况如下表15，图17所示，表明以本发明晶型CS2为活性成分的片剂具有良好的溶出度和溶出速率。
表15
Figure PCTCN2018095690-appb-000013
上述实施例只为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰，都应涵盖在本发明的保护范围之内。

Claims (15)

  1. 一种化合物(I)的晶型CS1，其特征在于，其X射线粉末衍射在衍射角2θ值为12.0°±0.2°、14.2°±0.2°、19.7°±0.2°处有特征峰。
  2. 根据权利要求1所述的晶型CS1，其特征还在于，其X射线粉末衍射在衍射角2θ值为17.4°±0.2°、21.1°±0.2°、27.9°±0.2°中的一处或多处有特征峰。
  3. 根据权利要求1所述的晶型CS1，其特征还在于，其X射线粉末衍射在衍射角2θ值为17.9°±0.2°、24.3°±0.2°、26.1°±0.2°的一处或多处有特征峰。
  4. 一种化合物(I)晶型CS1的制备方法，其特征在于，所述方法为：
    (1)将化合物(I)溶解在醇类溶剂体系中，添加反溶剂析晶，然后分离、干燥而获得；或
    (2)化合物(I)在40-70℃温度下溶解在酮类溶剂体系中，并于0-30℃温度下冷却析晶，分离，干燥得到；或
    (3)将化合物(I)加至卤代烷烃和腈类的混合溶剂中，于0-30℃条件下搅拌析晶得到。
  5. 根据权利要求4所述的制备方法，方法(1)中所述醇类溶剂为甲醇、或乙醇、或丙醇或它们的任意混合，所述析晶时间为0.5-24小时；方法(2)中所述酮类溶剂为丙酮、或甲基乙基酮、或甲基异丁基酮、或它们的任意混合，所述溶解温度为50℃，所述冷却温度为4℃，所述析晶时间为4-48小时；方法(3)中所述卤代烷烃类溶剂为氯仿，所述腈类溶剂为乙腈，所述卤代烷烃类溶剂和腈类溶剂的体积比(v:v)为1:15-15:1，所述搅拌温度为5℃。
  6. 根据权利要求5所述的制备方法，方法(1)中所述醇类溶剂为甲醇，所述反溶剂为水，所述析晶时间为2小时；方法(2)中所述酮类溶剂为甲基乙基酮，所述析晶时间为24小时；方法(3)所述卤代烷烃类溶剂和腈类溶剂的体积比(v:v)为3:1。
  7. 一种化合物(I)的晶型CS2，其特征在于，其X射线粉末衍射在衍射角2θ值为11.5°±0.2°、16.5°±0.2°、20.3°±0.2°处有特征峰。
  8. 根据权利要求7所述的晶型CS2，其特征还在于，其X射线粉末衍射在衍射角2θ值为4.1°±0.2°、21.7°±0.2°、22.4°±0.2°中的一处或多处有特征峰。
  9. 根据权利要求7所述的晶型CS2，其特征还在于，其X射线粉末衍射在衍射角2θ值为5.0°±0.2°、22.9°±0.2°、23.3°±0.2°的一处或多处有特征峰。
  10. 一种化合物(I)晶型CS2的制备方法，其特征在于，所述方法为：
    (1)将化合物(I)溶解在醇类和卤代烃类的混合溶剂中，后挥发而获得；或
    (2)将化合物(I)溶解在环醚类和水的混合溶剂或酮类溶剂中，后挥发而获得。
  11. 根据权利要求10所述的制备方法，方法(1)中所述醇类为甲醇、或乙醇、或异丙醇、或它 们的任意混合，所述卤代烃类溶剂为氯仿、或二氯甲烷、或者它们的混合，所述醇类和卤代烃的体积比(v:v)为1:5-5:1，所述析晶时间为2-10天；方法(2)中所述环醚类溶剂为1,4-二氧六环、或四氢呋喃、或者它们的混合，所述环醚类和水的体积比(v:v)为1:10-10:1，所述酮类溶剂为丁酮，所述析晶时间为2-30天。
  12. 根据权利要求11所述的制备方法，方法(1)中所述醇类为甲醇，所述卤代烃类溶剂为氯仿，所述醇类和卤代烃的体积比(v:v)为3:1，所述析晶时间为7天；方法(2)中所述环醚类溶剂为四氢呋喃，所述环醚类和水的体积比(v:v)为1:1，所述析晶时间为24天。
  13. 一种药物组合物，所述药物组合物包含有效治疗量的权利要求1中所述的晶型CS1、权利要求7中所述的晶型CS2或它们的任意混合及药学上可接受的载体、稀释剂或赋形剂。
  14. 权利要求1中所述的晶型CS1、权利要求7中所述的晶型CS2或它们的任意混合在制备前列腺素D2受体2拮抗剂药物制剂中的用途。
  15. 权利要求1中所述的晶型CS1、权利要求7中所述的晶型CS2或它们的任意混合在制备治疗哮喘和/或过敏性皮炎和/或过敏性鼻炎药物制剂中的用途。
PCT/CN2018/095690 2017-07-14 2018-07-13 Qaw-039的晶型及其制备方法和用途 WO2019011336A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710577126.9 2017-07-14
CN201710577126 2017-07-14

Publications (1)

Publication Number Publication Date
WO2019011336A1 true WO2019011336A1 (zh) 2019-01-17

Family

ID=65001049

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2018/095690 WO2019011336A1 (zh) 2017-07-14 2018-07-13 Qaw-039的晶型及其制备方法和用途
PCT/CN2018/095694 WO2019011337A1 (zh) 2017-07-14 2018-07-13 Qaw-039的晶型及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/095694 WO2019011337A1 (zh) 2017-07-14 2018-07-13 Qaw-039的晶型及其制备方法和用途

Country Status (1)

Country Link
WO (2) WO2019011336A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106188040A (zh) * 2016-06-28 2016-12-07 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法
WO2017056001A1 (en) * 2015-09-29 2017-04-06 Novartis Ag Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1h-pyrrolo [2,3-b]pyridin-3-yl-acetic acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017056001A1 (en) * 2015-09-29 2017-04-06 Novartis Ag Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1h-pyrrolo [2,3-b]pyridin-3-yl-acetic acid
CN106188040A (zh) * 2016-06-28 2016-12-07 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FANG, LIANG, PHARMACY, 31 March 2016 (2016-03-31), pages 48 - 52, ISBN: 978-7-5067-7405-5 *
SANDHAM, D.A. ET AL.: "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma", ACS MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 5, 25 April 2017 (2017-04-25), pages 582 - 586, XP002781657 *

Also Published As

Publication number Publication date
WO2019011337A1 (zh) 2019-01-17

Similar Documents

Publication Publication Date Title
WO2019052133A1 (zh) Gsk1278863的晶型及其制备方法和制药用途
JP2010535176A (ja) ジヒドロプテリジノン誘導体の結晶形
WO2017193914A1 (zh) 克立硼罗游离形式的晶型及其制备方法和用途
RU2704795C2 (ru) Кристаллическая форма бисульфата ингибитора jak и способ ее получения
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
WO2018050091A1 (zh) 奥扎莫德盐酸盐的晶型及其制备方法
WO2021244323A1 (zh) 一种乌帕替尼的晶型及其制备方法和用途
WO2019019959A1 (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
US10752595B2 (en) Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof
WO2018006870A1 (zh) Galunisertib的晶型及其制备方法和用途
WO2018133705A1 (zh) Gft-505的晶型及其制备方法和用途
WO2020244348A1 (zh) 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型
WO2020244349A1 (zh) 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
WO2018233437A1 (zh) 巴瑞克替尼的晶型及其制备方法
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
WO2019134455A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
WO2019011336A1 (zh) Qaw-039的晶型及其制备方法和用途
WO2019105388A1 (zh) 一种a3腺苷受体激动剂药物的晶型及其制备方法和用途
WO2017016512A1 (zh) 马赛替尼甲磺酸盐的新晶型及其制备方法
WO2018077187A1 (zh) Ap26113的新晶型及其制备方法
WO2018137670A1 (zh) 一种病毒蛋白抑制剂药物vx-787的晶型及其制备方法和用途
WO2018001335A1 (zh) Nbi-98854的晶型及其制备方法和用途
WO2018059531A1 (zh) 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
WO2017076358A1 (zh) 咪唑基联苯基化合物盐的新晶型及其制备方法
WO2016155631A1 (zh) 托吡司他的新晶型及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18831455

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18831455

Country of ref document: EP

Kind code of ref document: A1